Abich Financial Wealth Management LLC Acquires New Holdings in Amgen Inc. $AMGN

Abich Financial Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,541 shares of the medical research company’s stock, valued at approximately $435,000.

A number of other institutional investors have also recently bought and sold shares of the stock. TAGStone Capital Inc. lifted its position in Amgen by 0.8% in the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after acquiring an additional 32 shares in the last quarter. Wealth Quarterback LLC raised its stake in shares of Amgen by 1.6% in the 3rd quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock valued at $624,000 after purchasing an additional 34 shares during the period. DDFG Inc lifted its holdings in shares of Amgen by 1.1% in the third quarter. DDFG Inc now owns 3,014 shares of the medical research company’s stock valued at $850,000 after purchasing an additional 34 shares in the last quarter. Nicholson Wealth Management Group LLC lifted its holdings in shares of Amgen by 0.6% in the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock valued at $1,652,000 after purchasing an additional 35 shares in the last quarter. Finally, LS Investment Advisors LLC boosted its position in shares of Amgen by 4.1% during the third quarter. LS Investment Advisors LLC now owns 885 shares of the medical research company’s stock worth $250,000 after buying an additional 35 shares during the period. Institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.76% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN opened at $366.20 on Friday. The company has a market cap of $197.19 billion, a P/E ratio of 25.73, a P/E/G ratio of 3.75 and a beta of 0.46. The firm’s fifty day moving average price is $336.68 and its two-hundred day moving average price is $313.14. Amgen Inc. has a one year low of $261.43 and a one year high of $385.12. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter last year, the company posted $5.31 EPS. Amgen’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. Amgen’s dividend payout ratio (DPR) is currently 66.90%.

Analyst Upgrades and Downgrades

Several research firms have commented on AMGN. Citigroup boosted their target price on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. The Goldman Sachs Group increased their target price on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. BMO Capital Markets raised their target price on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Finally, Truist Financial lifted their price target on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Amgen currently has an average rating of “Moderate Buy” and a consensus price target of $354.04.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.